BioLargo, Inc. Stock OTC Bulletin Board
Equities
US09065A1007
Commodity Chemicals
End-of-day quote
Other stock markets
|
||
- USD | - |
05-14 | Transcript : BioLargo, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | BioLargo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 19.05M 25.95M | Sales 2025 * | 25.76M 35.11M | Capitalization | 86.78M 118M |
---|---|---|---|---|---|
Net income 2024 * | -1M -1.36M | Net income 2025 * | - 0 | EV / Sales 2024 * | 4.56 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.37 x |
P/E ratio 2024 * |
-29.2
x | P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.81% |
Latest transcript on BioLargo, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Dennis Calvert
CEO | Chief Executive Officer | 61 | 02-05-31 |
Charles Dargan
DFI | Director of Finance/CFO | 68 | 08-01-31 |
Chief Operating Officer | 55 | 02-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dennis Marshall
BRD | Director/Board Member | 81 | 06-04-27 |
Kenneth Code
CTO | Chief Tech/Sci/R&D Officer | 77 | 07-03-31 |
Dennis Calvert
CEO | Chief Executive Officer | 61 | 02-05-31 |
1st Jan change | Capi. | |
---|---|---|
+2.46% | 102B | |
-8.98% | 60.79B | |
+74.76% | 48.86B | |
+13.97% | 37.96B | |
+4.56% | 32.37B | |
+14.72% | 20.64B | |
+11.17% | 16.58B | |
+8.81% | 13.93B | |
-3.19% | 13.25B |